RT Journal Article SR Electronic T1 Factors Associated with Medicine Timing Effects: A Meta-analysis JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.10.24.21265348 DO 10.1101/2021.10.24.21265348 A1 Marc D. Ruben A1 Lauren J. Francey A1 Gang Wu A1 David F. Smith A1 Garret A. FitzGerald A1 Jacob J. Hughey A1 John B. Hogenesch YR 2021 UL http://medrxiv.org/content/early/2021/10/26/2021.10.24.21265348.abstract AB Importance Clinical evidence suggests that the time of day of treatment can affect outcomes in many different diseases, but this information is dispersed, imprecise, and heterogeneous. Consequently, practice guidelines and clinical care recommendations seldom specify intervention time.Objective To understand the sources of variability and summarize clinical findings on the time of day effects of medicine.Data Sources A systematic search of Pubmed, Google Scholar, and ClinicalTrials.gov for “chronotherapy” OR “time of administration”.Study Selection Any clinical study since 2000, randomized or observational, that compared the effects of treatment at different times of day. We included pharmacologic or surgical interventions having at least one continuous outcome.Data Extraction and Synthesis For selected studies, we extracted the mean and variance of each time-of-day treatment group. From these, we computed the standardized mean difference (SMD) as the measure of timing effect. Where a study reported multiple outcomes, we selected a single outcome based on a defined order of priority.Main Outcomes and Measures We estimated overall pooled effect size and heterogeneity by a random effects model, followed by outlier detection and subgroup analyses to evaluate how study factors, including drug, design, outcome, and source, associate with timing effect.Results 78 studies met the inclusion criteria, comprising 48 distinct interventions over many therapeutic areas. We found an overall effect of time on clinical outcomes but with substantial heterogeneity between studies. Predicted effects range from none to large depending on the study context. Study size, registration status, and source are associated with the magnitude of effect. Larger trials and those that were pre-registered have markedly smaller effects, suggesting that the published record overstates the effects of the timing of medicine on clinical outcomes. In particular, the notion that antihypertensives are more effective if taken at bedtime draws disproportionately from one source in the field, which consistently detects larger effects than the community average. Lastly, among the most highly studied drug timing relationships, aspirin’s anti-clotting effect stands out, consistently favoring evening over morning dosing.Conclusions and Relevance While accounts of drug timing effects have focused on yes/no, appreciating the range of probable effects may help clarify where ‘circadian medicine’ meets the threshold for clinical benefit.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Institute of Neurological Disorders and Stroke (2R01NS054794 to JBH and Andrew Liu), the National Heart, Lung, and Blood Institute (R01HL138551 to Eric Bittman and JBH), and National Cancer Institute (1R01CA22748501A1 to Ron Anafi and JBH).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was not submitted for institutional review board approval because it did not involve individual patient information and all data extraction was from publicly available sources including published research articles and ClinicalTrials.gov trial results.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in this study are available upon request to the authors. However, all data produced can also be replicated by source code available on github and metadata available as a supplemental file.